Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

StarTric - A novel transcatheter medical device to treat Tricuspid Regurgitation

Ziel

"Tricuspid Regurgitation (TR) poses a significant health challenge, affecting millions worldwide. Current treatment options, primarily open-heart surgery, come with inherent risks and are often unsuitable for frail patients. StarTric has pioneered a transcatheter device tailored to the intricate task of addressing TR. Drawing inspiration from the highly successful open-heart ""clover"" technique, this innovative device offers a minimally invasive alternative for TR repair. The StarTric device will reshape the tricuspid valve into a clover-like configuration, effectively restoring proper valve function. By replicating the efficacy of the clover procedure through transcatheter means, StarTric's solution holds immense promise in transforming the lives of countless patients globally. To bring this breakthrough solution to patients in need, StarTric requires funding support to accelerate development, clinical trials, regulatory approval and commercial efforts."

Wissenschaftliches Gebiet (EuroSciVoc)

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-EIC-ACC - HORIZON EIC Accelerator

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) HORIZON-EIC-2024-ACCELERATOR-02

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Koordinator

STAR TRIC SRL
Netto-EU-Beitrag
€ 2 499 999,00
Adresse
Via della Moscova , 3 - 20121
20121 Milano
Italien
KMU
Ja
Region
Nord-Ovest Lombardia Milano
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
Keine Daten